Abstract
Detecting all workplace asymptomatic COVID-19 virus spreaders would require daily testing of employees, which is not practical. Over a two week period, nine workplace locations were chosen to test employees for SARS-CoV-2 infection (841 tests) and high-frequency-touch point environmental surfaces (5,500 tests) for Coronavirus using Eurofins COVID-19 Sentinel™ RT-PCR methods. Of the 9 locations, 3 had one or employees infected with SARS-CoV-2, neither of whom had symptoms at the time of testing nor developed symptoms. Locations with Coronavirus contaminated surfaces were 10 times more likely to have clinically positive employees than locations with no or very few positive surfaces. Break room chairs, workbenches, and door handles were the most frequently contaminated surfaces. Coronavirus RNA was detected at very low concentrations (RT-PCR 34 to 38 Cq). Environmental monitoring can be used to validate intervention strategies and be useful to verify the effectiveness of such strategies on a regular basis.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
David C. Drovetta, Director of Regulatory Affairs and Quality Assurance at Viracor Eurofins, has a written letter (see supplemental file) stating that the study design has met their ethics and privacy policy, including signed informed consent of all study volunteers and acknowledgement that results will be submitted for publication. Volunteers were tested for SARS-CoV-2 and the study did not include a clinical trail.
Funding Statement
Funding for this study was provided by the participating locations and participating laboratories. No authors or institutions received payment or services from a third party.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
David C. Drovetta, Director of Regulatory Affairs and Quality Assurance at Viracor Eurofins, has a written letter (see supplemental file) stating that the study design has met their ethics and privacy policy, including signed informed consent of all study volunteers and acknowledgement that results will be submitted for publication. Volunteers were tested for SARS-CoV-2 and the study did not include a clinical trail.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available from the corresponding author.
